• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双特异性抗体穿梭靶向 CD98hc 介导 IgG 高效且持久的脑部递释。

Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs.

机构信息

Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.

Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA; Program in Chemical Biology, University of Michigan, Ann Arbor, MI 48109, USA.

出版信息

Cell Chem Biol. 2024 Feb 15;31(2):361-372.e8. doi: 10.1016/j.chembiol.2023.09.008. Epub 2023 Oct 26.

DOI:10.1016/j.chembiol.2023.09.008
PMID:37890480
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10922565/
Abstract

The inability of antibodies to penetrate the blood-brain barrier (BBB) is a key limitation to their use in diverse applications. One promising strategy is to deliver IgGs using a bispecific BBB shuttle, which involves fusing an IgG to a second affinity ligand that engages a cerebrovascular endothelial target and facilitates transport across the BBB. Nearly all prior efforts have focused on shuttles that target transferrin receptor (TfR-1) despite inherent delivery and safety challenges. Here, we report bispecific antibody shuttles that engage CD98hc, the heavy chain of the large neutral amino acid transporter (LAT1), and efficiently transport IgGs into the brain. Notably, CD98hc shuttles lead to much longer-lived brain retention of IgGs than TfR-1 shuttles while enabling more specific targeting due to limited CD98hc engagement in the brain parenchyma, which we demonstrate for IgGs that either agonize a neuronal receptor (TrkB) or target other endogenous cell-surface proteins on neurons and astrocytes.

摘要

抗体无法穿透血脑屏障 (BBB),这是其在各种应用中使用的一个关键限制。一种有前途的策略是使用双特异性 BBB 穿梭物来输送 IgG,这涉及将 IgG 融合到第二个亲和配体上,该配体与脑血管内皮细胞靶标结合,并促进穿过 BBB 的转运。尽管存在固有传递和安全挑战,但几乎所有先前的努力都集中在针对转铁蛋白受体 (TfR-1) 的穿梭物上。在这里,我们报告了与 CD98hc 结合的双特异性抗体穿梭物,CD98hc 是大型中性氨基酸转运蛋白 (LAT1) 的重链,可有效将 IgG 转运到大脑中。值得注意的是,与 TfR-1 穿梭物相比,CD98hc 穿梭物使 IgG 在大脑中的半衰期更长,同时由于 CD98hc 在脑实质中的结合有限,因此能够更特异性地靶向,我们针对在神经元和星形胶质细胞上既激动神经元受体 (TrkB) 又靶向其他内源性细胞表面蛋白的 IgG 证明了这一点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0010/10922565/480383429542/nihms-1938762-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0010/10922565/7dcb93d7f1a7/nihms-1938762-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0010/10922565/903e578c5aa2/nihms-1938762-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0010/10922565/780b635a1134/nihms-1938762-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0010/10922565/840ea03d4ccb/nihms-1938762-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0010/10922565/b2d0d8b04c9c/nihms-1938762-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0010/10922565/8946c3a3fc88/nihms-1938762-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0010/10922565/480383429542/nihms-1938762-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0010/10922565/7dcb93d7f1a7/nihms-1938762-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0010/10922565/903e578c5aa2/nihms-1938762-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0010/10922565/780b635a1134/nihms-1938762-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0010/10922565/840ea03d4ccb/nihms-1938762-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0010/10922565/b2d0d8b04c9c/nihms-1938762-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0010/10922565/8946c3a3fc88/nihms-1938762-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0010/10922565/480383429542/nihms-1938762-f0008.jpg

相似文献

1
Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs.双特异性抗体穿梭靶向 CD98hc 介导 IgG 高效且持久的脑部递释。
Cell Chem Biol. 2024 Feb 15;31(2):361-372.e8. doi: 10.1016/j.chembiol.2023.09.008. Epub 2023 Oct 26.
2
Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs.靶向CD98重链的双特异性抗体转运体介导IgG高效且持久地递送至脑内。
bioRxiv. 2023 Apr 29:2023.04.29.538811. doi: 10.1101/2023.04.29.538811.
3
Comparative Radiotracing Quantifies Brain Cellular Uptake and Catabolism of Bispecific Antibodies Targeting Transferrin Receptor and CD98hc.比较放射性示踪法定量分析靶向转铁蛋白受体和CD98重链的双特异性抗体的脑内细胞摄取及分解代谢情况。
ACS Chem Neurosci. 2025 Apr 2;16(7):1264-1274. doi: 10.1021/acschemneuro.4c00552. Epub 2025 Mar 12.
4
Transcytosis of payloads that are non-covalently complexed to bispecific antibodies across the hCMEC/D3 blood-brain barrier model.双特异性抗体非共价复合物所载货物穿过 hCMEC/D3 血脑屏障模型的转胞吞作用。
Biol Chem. 2018 Jun 27;399(7):711-721. doi: 10.1515/hsz-2017-0311.
5
CD98hc is a target for brain delivery of biotherapeutics.CD98hc 是脑内递送生物治疗药物的靶点。
Nat Commun. 2023 Aug 19;14(1):5053. doi: 10.1038/s41467-023-40681-4.
6
A shorter linker in the bispecific antibody RmAb158-scFv8D3 improves TfR-mediated blood-brain barrier transcytosis in vitro.双特异性抗体RmAb158-scFv8D3中较短的连接子可改善体外转铁蛋白受体介导的血脑屏障转胞吞作用。
Sci Rep. 2024 Dec 23;14(1):30613. doi: 10.1038/s41598-024-83627-6.
7
Brain penetration, target engagement, and disposition of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1.代谢型谷氨酸受体1的血脑屏障穿透性双特异性抗体拮抗剂的脑渗透、靶点结合及处置情况
FASEB J. 2016 May;30(5):1927-40. doi: 10.1096/fj.201500078. Epub 2016 Feb 2.
8
Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody.利用转铁蛋白受体单克隆抗体进行IgG融合蛋白的血脑屏障药物递送
Expert Opin Drug Deliv. 2015 Feb;12(2):207-22. doi: 10.1517/17425247.2014.952627. Epub 2014 Aug 20.
9
Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants.转铁蛋白受体(TfR)转运决定了 TfR 抗体亲和力变体在大脑中的摄取。
J Exp Med. 2014 Feb 10;211(2):233-44. doi: 10.1084/jem.20131660. Epub 2014 Jan 27.
10
Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain.双特异性TfR/BACE1抗体用于优化脑内抗体摄取的数学药代动力学/药效学及安全性模型。
Eur J Pharm Biopharm. 2016 Apr;101:53-61. doi: 10.1016/j.ejpb.2016.01.009. Epub 2016 Jan 25.

引用本文的文献

1
Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria.用于治疗药物脑递送的受体介导转胞吞作用:受体类别与标准
Front Drug Deliv. 2024 Mar 12;4:1360302. doi: 10.3389/fddev.2024.1360302. eCollection 2024.
2
Transferrin receptor-mediated transport at the blood-brain barrier is elevated during early development and maintained across aging and in an Alzheimer's mouse model.在早期发育过程中,血脑屏障处转铁蛋白受体介导的转运增加,并在衰老过程中以及阿尔茨海默病小鼠模型中持续存在。
J Cereb Blood Flow Metab. 2025 Aug 16:271678X251361997. doi: 10.1177/0271678X251361997.
3
Development of a Novel Immunoprecipitation Method for Extracting Monoclonal Antibodies From Brain Tissue and Its Application to Assessing In Vivo Brain Penetration in Mouse via Liquid Chromatography-Mass Spectrometry.

本文引用的文献

1
Reduction of therapeutic antibody self-association using yeast-display selections and machine learning.利用酵母展示筛选和机器学习降低治疗性抗体的自缔合。
MAbs. 2022 Jan-Dec;14(1):2146629. doi: 10.1080/19420862.2022.2146629.
2
Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis.通过具有内在受体介导吞噬作用的跨内皮迁移体增强抗体穿过血脑屏障的递送。
Med. 2022 Dec 9;3(12):860-882.e15. doi: 10.1016/j.medj.2022.09.007. Epub 2022 Oct 17.
3
Monoclonal Antibody Therapy in Parkinson's Disease - The End?
一种从脑组织中提取单克隆抗体的新型免疫沉淀方法的开发及其通过液相色谱-质谱法评估小鼠体内脑渗透的应用。
Biomed Chromatogr. 2025 Sep;39(9):e70196. doi: 10.1002/bmc.70196.
4
Recent Advances in Antibody Therapy for Alzheimer's Disease: Focus on Bispecific Antibodies.阿尔茨海默病抗体治疗的最新进展:聚焦双特异性抗体
Int J Mol Sci. 2025 Jun 28;26(13):6271. doi: 10.3390/ijms26136271.
5
Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies.用于转铁蛋白受体介导的抗体脑内递送的转化型最小生理药代动力学模型
MAbs. 2025 Dec;17(1):2515414. doi: 10.1080/19420862.2025.2515414. Epub 2025 Jun 26.
6
Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease.用于治疗阿尔茨海默病的双特异性脑穿透抗体。
J Prev Alzheimers Dis. 2025 Sep;12(8):100214. doi: 10.1016/j.tjpad.2025.100214. Epub 2025 May 26.
7
Drug delivery strategies to cross the blood-brain barrier in Alzheimer's disease: a comprehensive review on three promising strategies.阿尔茨海默病中跨越血脑屏障的药物递送策略:对三种有前景策略的全面综述
J Prev Alzheimers Dis. 2025 Aug;12(7):100204. doi: 10.1016/j.tjpad.2025.100204. Epub 2025 May 19.
8
Recent advances in nanomaterial-based brain-targeted delivery systems for glioblastoma therapy.基于纳米材料的胶质母细胞瘤治疗脑靶向递送系统的最新进展。
Nanomedicine (Lond). 2025 Jun;20(12):1495-1511. doi: 10.1080/17435889.2025.2503694. Epub 2025 May 12.
9
New Transferrin Receptor-Targeting Conjugate Effectively Delivers DNA to Mouse Brain.新型转铁蛋白受体靶向共轭物可有效将DNA递送至小鼠大脑。
Angew Chem Int Ed Engl. 2025 Jun 10;64(24):e202500247. doi: 10.1002/anie.202500247. Epub 2025 Apr 10.
10
Nanotechnology to Overcome Blood-Brain Barrier Permeability and Damage in Neurodegenerative Diseases.纳米技术克服神经退行性疾病中的血脑屏障通透性及损伤
Pharmaceutics. 2025 Feb 20;17(3):281. doi: 10.3390/pharmaceutics17030281.
帕金森病中的单克隆抗体疗法——终结?
N Engl J Med. 2022 Aug 4;387(5):466-467. doi: 10.1056/NEJMe2207681.
4
Trial of Prasinezumab in Early-Stage Parkinson's Disease.普拉克索尼单抗治疗早期帕金森病的试验。
N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867.
5
Trial of Cinpanemab in Early Parkinson's Disease.西尼潘单抗治疗早期帕金森病的临床试验。
N Engl J Med. 2022 Aug 4;387(5):408-420. doi: 10.1056/NEJMoa2203395.
6
A Single Domain Shark Antibody Targeting the Transferrin Receptor 1 Delivers a TrkB Agonist Antibody to the Brain and Provides Full Neuroprotection in a Mouse Model of Parkinson's Disease.一种靶向转铁蛋白受体1的单域鲨鱼抗体将TrkB激动剂抗体递送至大脑,并在帕金森病小鼠模型中提供完全的神经保护作用。
Pharmaceutics. 2022 Jun 24;14(7):1335. doi: 10.3390/pharmaceutics14071335.
7
Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space.使用能够推广到新突变空间的机器学习模型来优化治疗性抗体的亲和力和特异性。
Nat Commun. 2022 Jul 1;13(1):3788. doi: 10.1038/s41467-022-31457-3.
8
Treating Parkinson's Disease via Activation of BDNF/TrkB Signaling Pathways and Inhibition of Delta-Secretase.通过激活脑源性神经营养因子/TrkB 信号通路和抑制 δ-分泌酶治疗帕金森病。
Neurotherapeutics. 2022 Jul;19(4):1283-1297. doi: 10.1007/s13311-022-01248-1. Epub 2022 May 20.
9
A hybridoma-derived monoclonal antibody with high homology to the aberrant myeloma light chain.与异常骨髓瘤轻链具有高度同源性的杂交瘤衍生的单克隆抗体。
PLoS One. 2021 Oct 11;16(10):e0252558. doi: 10.1371/journal.pone.0252558. eCollection 2021.
10
Nucleic acid delivery for therapeutic applications.治疗应用的核酸递送。
Adv Drug Deliv Rev. 2021 Nov;178:113834. doi: 10.1016/j.addr.2021.113834. Epub 2021 Sep 4.